LT3611192T - T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu - Google Patents

T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu

Info

Publication number
LT3611192T
LT3611192T LTEP19186738.1T LT19186738T LT3611192T LT 3611192 T LT3611192 T LT 3611192T LT 19186738 T LT19186738 T LT 19186738T LT 3611192 T LT3611192 T LT 3611192T
Authority
LT
Lithuania
Prior art keywords
tcr alpha
polypeptides based
cell recruiting
reactivity
beta
Prior art date
Application number
LTEP19186738.1T
Other languages
English (en)
Inventor
Annelies Roobrouck
Diane Van Hoorick
João VIEIRA
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of LT3611192T publication Critical patent/LT3611192T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP19186738.1T 2015-05-13 2016-05-13 T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu LT3611192T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160757P 2015-05-13 2015-05-13
US201662319486P 2016-04-07 2016-04-07

Publications (1)

Publication Number Publication Date
LT3611192T true LT3611192T (lt) 2025-06-25

Family

ID=55971005

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP19186738.1T LT3611192T (lt) 2015-05-13 2016-05-13 T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
LT16722887T LT3294768T (lt) 2015-05-13 2016-05-13 T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu

Family Applications After (1)

Application Number Title Priority Date Filing Date
LT16722887T LT3294768T (lt) 2015-05-13 2016-05-13 T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu

Country Status (16)

Country Link
US (2) US10927186B2 (lt)
EP (3) EP4524163A3 (lt)
AU (4) AU2016259792B2 (lt)
CA (1) CA2985698C (lt)
CY (1) CY1122675T1 (lt)
DK (2) DK3611192T3 (lt)
ES (2) ES2754427T3 (lt)
FI (1) FI3611192T3 (lt)
HR (2) HRP20250651T1 (lt)
HU (2) HUE071467T2 (lt)
LT (2) LT3611192T (lt)
PL (2) PL3294768T3 (lt)
PT (2) PT3294768T (lt)
RS (2) RS66859B1 (lt)
SI (2) SI3611192T1 (lt)
WO (1) WO2016180969A1 (lt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
IL317416A (en) 2016-11-16 2025-02-01 Ablynx Nv T cell-recruiting polypeptides capable of binding CD123 and TCR alpha/beta
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
EP3551656A1 (en) * 2016-12-07 2019-10-16 Ablynx NV Improved serum albumin binding immunoglobulin single variable domains
CN117285623A (zh) 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
DK3571224T3 (da) 2017-01-17 2024-11-11 Ablynx Nv Forbedrede serumalbuminbindere
WO2019051102A2 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020204686A1 (en) * 2019-01-04 2021-07-22 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
WO2020172631A2 (en) 2019-02-21 2020-08-27 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
WO2022032029A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il28a receptor binding synthetic cytokines and methods of use
US12012457B1 (en) 2020-08-05 2024-06-18 Synthekine, Inc. IL23R binding molecules and methods of use
WO2022031870A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL27Rα BINDING MOLECULES AND METHODS OF USE
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
BR112023001723A2 (pt) 2020-08-05 2023-05-02 Synthekine Inc Moléculas de ligação à gp130 e métodos de uso
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
EP4192880A4 (en) 2020-08-05 2025-04-30 Synthekine, Inc. IL10 receptor-binding molecules and methods of use
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
JP7819178B2 (ja) 2020-08-05 2026-02-24 シンセカイン インコーポレイテッド ＩＬ１０Ｒｂ結合分子および使用方法
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
CN116829585A (zh) 2020-08-05 2023-09-29 辛德凯因股份有限公司 Il27受体结合相关的组合物和方法
CA3203141A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
JP2024509027A (ja) * 2020-12-18 2024-02-29 アブリンクス エン．ヴェー． Ｔｃｒアルファ／ベータの反応性に基づくｔ細胞動員ポリペプチド
TW202241947A (zh) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽
WO2022152862A1 (en) * 2021-01-14 2022-07-21 Institut Curie Her2 single domain antibodies variants and cars thereof
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
AU2022409733A1 (en) * 2021-12-17 2024-08-01 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
CA3259417A1 (en) 2022-06-14 2023-12-21 Ablynx Nv UNIQUE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETING THE T LYMPHOCYTE RECEPTOR
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
AR133725A1 (es) 2023-09-04 2025-10-29 Sanofi Sa Polipéptidos para uso en el tratamiento de tumores que expresan glipicano-3
AR134512A1 (es) 2023-12-01 2026-01-21 Ablynx Nv Polipéptidos activados con precisión
WO2025140489A1 (en) * 2023-12-29 2025-07-03 Vibrant Pharma Limited Multispecific antibodies and uses thereof
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2026052756A1 (en) 2024-09-05 2026-03-12 Ablynx Nv Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
WO2026078159A1 (en) * 2024-10-10 2026-04-16 Ablynx Nv Immune cell engagers and methods comprising the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
ES2155854T3 (es) 1993-06-09 2001-06-01 Unilever Nv Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado.
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
CN1316910A (zh) 1998-02-19 2001-10-10 埃克斯西特治疗公司 用于调节淋巴细胞活化的组合物及方法
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003014960A2 (en) 2001-08-03 2003-02-20 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7958021B2 (en) 2002-09-10 2011-06-07 Igt Method and device for collecting and reporting data
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
MXPA06014075A (es) * 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008068280A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
HUE053480T2 (hu) 2009-04-30 2021-06-28 Ablynx Nv Eljárás domén ellenanyagok elõállítására
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
ES2660895T3 (es) 2010-10-29 2018-03-26 Ablynx N.V. Método para la producción de dominios variables individuales de inmunoglobulina
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
AU2013201422B2 (en) * 2012-01-23 2015-04-09 Ablynx Nv Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
US20140154253A1 (en) 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
CN105531374A (zh) * 2013-07-12 2016-04-27 酵活有限公司 双特异性cd3和cd19抗原结合构建体
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
KR102093343B1 (ko) 2013-10-23 2020-03-25 삼성전자주식회사 이미지 센서 및 이미지 센서를 구동하는 방법
IL317416A (en) * 2016-11-16 2025-02-01 Ablynx Nv T cell-recruiting polypeptides capable of binding CD123 and TCR alpha/beta
TW202241947A (zh) * 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽

Also Published As

Publication number Publication date
LT3294768T (lt) 2019-11-11
EP3611192A2 (en) 2020-02-19
RS66859B1 (sr) 2025-06-30
HRP20250651T1 (hr) 2025-07-18
EP4524163A2 (en) 2025-03-19
US20210395398A1 (en) 2021-12-23
EP3611192B1 (en) 2025-03-05
EP3294768B1 (en) 2019-08-21
DK3611192T3 (da) 2025-06-10
SI3294768T1 (sl) 2019-11-29
US20190112392A1 (en) 2019-04-18
ES3031002T3 (en) 2025-07-03
HUE045437T2 (hu) 2019-12-30
AU2021232753A1 (en) 2021-10-14
AU2021232753B2 (en) 2024-10-24
AU2016259792B2 (en) 2019-07-25
ES2754427T3 (es) 2020-04-17
FI3611192T3 (fi) 2025-06-17
PL3611192T3 (pl) 2025-07-07
AU2019236588B2 (en) 2021-10-07
RS59376B1 (sr) 2019-11-29
US10927186B2 (en) 2021-02-23
PT3294768T (pt) 2019-11-05
DK3294768T3 (da) 2019-11-11
EP4524163A3 (en) 2025-06-11
HUE071467T2 (hu) 2025-08-28
AU2024200553A1 (en) 2024-02-22
AU2019236588A1 (en) 2019-10-17
CA2985698A1 (en) 2016-11-17
EP3294768A1 (en) 2018-03-21
AU2016259792A1 (en) 2017-12-14
PT3611192T (pt) 2025-06-12
CA2985698C (en) 2023-02-28
EP3611192A3 (en) 2020-03-25
HRP20191800T1 (hr) 2019-12-27
SI3611192T1 (sl) 2025-07-31
CY1122675T1 (el) 2021-03-12
PL3294768T3 (pl) 2020-03-31
WO2016180969A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
PT3294768T (pt) Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
HUE067423T2 (hu) CD3-reaktivitáson alapulva T-sejtet toborzó polipeptidek
IL266506A (en) t-cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
GB201507368D0 (en) Cell
GB201503500D0 (en) Cell
GB201514874D0 (en) Cell
GB201518817D0 (en) Cell
PL3125302T3 (pl) Ogniwo słoneczne
IL261390B (en) Digital unit cell with analog counter element
GB201504367D0 (en) Electroactive materials for metal-lon batteries
GB201511452D0 (en) Aircraft fuel measurement
SG11201708313QA (en) T cell receptor
GB201521284D0 (en) Fuel cell
PL3529267T3 (pl) Receptor komórek t
PL3252846T3 (pl) Zespół ogniwa akumulatora
PL3246965T3 (pl) Zespół ogniw baterii
GB201521182D0 (en) An improved conveyer weigh cell module
PL3139162T3 (pl) Urządzenie pomiarowe z ruchomą komórką pomiarową
GB201711783D0 (en) Nuclear Microbattery
GB2566610B (en) Fuel cell unit
GB2539233B (en) Electrochemical cell
GB201509444D0 (en) Solid oxide fuel cell unit
PL3128579T3 (pl) Ogniwo baterii
GB201512411D0 (en) Fuel cell system
TWI560892B (en) Solar cell